Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B McGovern

Showing results (191-200 of 275) with videos related to

Pageof 28
Sort By:
Frontiers in Medicine|August 6, 2019
Novel Microbial-Based Immunotherapy Approach for Crohn's DiseaseSimon Sutcliffe, Shirin Kalyan, Jim Pankovich, et al.
Inflammatory Bowel Diseases|February 4, 2014
Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patientsAdam Weizman, Brian Huang, Dror Berel, et al.
Human Molecular Genetics|June 24, 2010
Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's diseaseDermot P B McGovern, Michelle R Jones, Kent D Taylor, et al.
Cell Host & Microbe|March 10, 2019
Malassezia Is Associated with Crohn's Disease and Exacerbates Colitis in Mouse ModelsJose J Limon, Jie Tang, Dalin Li, et al.
Science (New York, N.Y.)|May 28, 2016
Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel diseaseHiutung Chu, Arya Khosravi, Indah P Kusumawardhani, et al.
The Journal of Biological Chemistry|December 3, 2016
The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD)Olga F Sarmento, Phyllis A Svingen, Yuning Xiong, et al.
Inflammatory Bowel Diseases|May 14, 2013
Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's diseaseMarla C Dubinsky, Subra Kugathasan, Soonil Kwon, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 studyW J Sandborn, G Y Melmed, D P B McGovern, et al.
Inflammatory Bowel Diseases|July 11, 2022
The Current State of Care for Black and Hispanic Inflammatory Bowel Disease PatientsJulia J Liu, Bincy P Abraham, Paula Adamson, et al.
Journal of Crohn'S & Colitis|June 16, 2018
An Intergenic Variant rs9268877 Between HLA-DRA and HLA-DRB Contributes to the Clinical Course and Long-term Outcome of Ulcerative ColitisHo-Su Lee, Suk-Kyun Yang, Myunghee Hong, et al.
Pageof 28

Showing results (191-200 of 275) with videos related to

Sort By:
Pageof 28
Frontiers in Medicine|August 6, 2019
Novel Microbial-Based Immunotherapy Approach for Crohn's DiseaseSimon Sutcliffe, Shirin Kalyan, Jim Pankovich, et al.
Inflammatory Bowel Diseases|February 4, 2014
Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patientsAdam Weizman, Brian Huang, Dror Berel, et al.
Human Molecular Genetics|June 24, 2010
Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's diseaseDermot P B McGovern, Michelle R Jones, Kent D Taylor, et al.
Cell Host & Microbe|March 10, 2019
Malassezia Is Associated with Crohn's Disease and Exacerbates Colitis in Mouse ModelsJose J Limon, Jie Tang, Dalin Li, et al.
Science (New York, N.Y.)|May 28, 2016
Gene-microbiota interactions contribute to the pathogenesis of inflammatory bowel diseaseHiutung Chu, Arya Khosravi, Indah P Kusumawardhani, et al.
The Journal of Biological Chemistry|December 3, 2016
The Role of the Histone Methyltransferase Enhancer of Zeste Homolog 2 (EZH2) in the Pathobiological Mechanisms Underlying Inflammatory Bowel Disease (IBD)Olga F Sarmento, Phyllis A Svingen, Yuning Xiong, et al.
Inflammatory Bowel Diseases|May 14, 2013
Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's diseaseMarla C Dubinsky, Subra Kugathasan, Soonil Kwon, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 studyW J Sandborn, G Y Melmed, D P B McGovern, et al.
Inflammatory Bowel Diseases|July 11, 2022
The Current State of Care for Black and Hispanic Inflammatory Bowel Disease PatientsJulia J Liu, Bincy P Abraham, Paula Adamson, et al.
Journal of Crohn'S & Colitis|June 16, 2018
An Intergenic Variant rs9268877 Between HLA-DRA and HLA-DRB Contributes to the Clinical Course and Long-term Outcome of Ulcerative ColitisHo-Su Lee, Suk-Kyun Yang, Myunghee Hong, et al.
Pageof 28